BOSTON, Feb. 20, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, reported ...
BOSTON, July 11, 2022 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (RNAZ), the RNA oncology company committed to defeating cancer using RNA therapeutics, today announced extension of its ...
While great strides have been made in exploring the world of RNA, mysteries remain—and one approach to solving them is to look at what exactly a strand of RNA is doing in a cell in real time. At a ...
(RTTNews) - TransCode Therapeutics, Inc. (RNAZ) Thursday announced that its Safety Review Committee or SRC has approved the opening of the fourth patient cohort in its Phase I clinical trial for ...
BOSTON, March 27, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ), the RNA oncology company committed to more effectively treating cancer using RNA therapeutics, today announced that ...
RNA pioneer and biotechnology innovator joins TransCode Therapeutics Science Advisory Board to advance RNA oncology Dr. Zamore co-founded Alnylam Pharmaceuticals in 2002, which developed and ...
The MarketWatch News Department was not involved in the creation of this content. -- TransCode acquires 100% of the issued and outstanding interests of Polynoma from CK Life Sciences -- Concurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback